

Supplementary Table S1: Comparison of the characteristics of patients who did and did not meet FiRST criteria for fibromyalgia.

	FiRST criteria + N=36	FiRST criteria - N=85	p-value	Effect size [95% CI]
Age (years)	67.8 ± 11.9	63.5 ± 11.9	0.07	0.35 [-0.03 ; 0.75]
Age upon diagnosis (years)	50.7 ± 11.8	47.5 ± 12.4	0.1	0.26 [-0.13 ; 0.66]
Time since diagnosis (years), median [IQR]	15 [13 ; 18.4]	17 [13.2 ; 19.8]	0.3	0.14 [-0.25 ; 0.53]
Females	33 (91.7)	83 (97.7)	0.1	0.06 [-0.04 ; 0.16]
ESSPRI	7.2 ± 1.5	5.5 ± 1.9	<0.0001	0.98 [0.55 ; 1.39]
Dryness	7.6 ± 1.5	6.3 ± 2.5	0.001	0.57 [0.16 ; 0.97]
Fatigue	7.7 ± 1.8	6.0 ± 2.4	0.0001	0.73 [0.32 ; 1.14]
Pain	6.7 ± 2.2	4.1 ± 2.6	<0.0001	1.07 [0.64 ; 1.49]
Unstimulated salivary flow ≤ 0.01 mL/min	16 (47.1)	46 (56.1)	0.4	0.09 [-0.11 ; 0.29]
Schirmer's test ≤ 5 mm	24 (75.0)	49 (65.3)	0.4	0.10 [-0.09 ; 0.28]
ESSDAI	4.1 ± 4.3	4.1 ± 5.2	1	0.001 [-0.40 ; 0.40]
ESSDAI ≥ 5	11 (33.3)	24 (28.9)	0.7	0.04 [-0.14 ; 0.23]
Lymphoma	3 (8.3)	8 (9.4)	1	0.01 [-0.10 ; 0.12]
HAD anxiety on ASSESS inclusion	11.2 ± 4.7	9.2 ± 3.7	0.03	0.51 [0.08 ; 0.93]
HAD depression on ASSESS inclusion	7.7 ± 4.3	5.2 ± 3.3	0.005	0.71 [0.28 ; 1.14]
Anti-SSA	21 (58.3)	58 (68.2)	0.3	0.10 [-0.09 ; 0.29]
Anti-SSB	11 (30.6)	35 (41.2)	0.3	0.11 [-0.08 ; 0.29]
Focus ≥ 1	29 (90.6)	69 (92.0)	1	0.01 [-0.10 ; 0.13]
ESR (mm/h) (n=87), median [IQR]	17 [8 ; 32]	15.5 [9 ; 30]	0.9	0.03 [-0.40 ; 0.47]
C-reactive protein (mg/L) (n=108)	7.3 ± 17.1	3.5 ± 9.0	0.1	0.34 [-0.06 ; 0.74]
Gammaglobulin (g/L) (n=107), median [IQR]	11.8 [9.3 ; 13.6]	13.6 [11.1 ; 16.9]	0.01	0.42 [0.01 ; 0.83]
Corticosteroids	5 (13.9)	15 (17.6)	0.8	0.04 [-0.10 ; 0.18]
Immunosuppressive drugs	4 (11.1)	13 (15.3)	0.8	0.04 [-0.09 ; 0.17]
Corticosteroids or immunosuppressive drugs	8 (22.2)	23 (27.1)	0.6	0.05 [-0.12 ; 0.21]
Hydroxychloroquine	13 (36.1)	26 (30.6)	0.6	0.06 [-0.13 ; 0.24]
Antidepressants	8 (22.2)	8 (9.4)	0.08	0.13 [-0.02 ; 0.28]
Anxiolytics	9 (25)	7 (8.3)	0.02	0.17 [0.01 ; 0.32]
Antidepressants or anxiolytics, n (%)	13 (36.1)	13 (15.3)	0.01	0.21 [0.03 ; 0.38]

Data are given as mean ± SD or n (%) unless otherwise noted.

FiRST: Fibromyalgia Rapid Screening Tool; C: confidence interval; SD: standard deviation; IQR: interquartile range; ESR: erythrocyte sedimentation rate; ESSPRI: EULAR Sjögren's Syndrome Patient Reported Index; ESSDAI: EULAR Sjögren's Syndrome Disease Activity Index; HAD: Hospital Anxiety and Depression scale; ASSESS: Assessment of Systemic Signs and Evolution in Sjögren's Syndrome cohort; NS: not significant.

Supplementary Table S2: Comparison of the characteristics of patients who did and did not meet ACR 1990 criteria for fibromyalgia.

	ACR 90 criteria + N=22	ACR 90 criteria - N=99	p-value	Effect size [95% CI]
Age (years)	64.2 ± 11.8	64.9 ± 12.1	0.8	0.06 [-0.40 ; 0.51]
Age upon diagnosis (years)	47.0 ± 11.9	48.7 ± 12.4	0.6	0.14 [-0.33 ; 0.61]
Time since diagnosis (years), median [IQR]	17 [12.8 ; 19.5]	15 [13.1 ; 18.8]	0.7	0.04 [-0.43 ; 0.51]
Females	21 (95.5)	95 (96.0)	1	0.005 [-0.09 ; 0.10]
ESSPRI	7.4 ± 1.2	5.6 ± 2.0	<0.0001	0.94 [0.46 ; 1.42]
Dryness	7.7 ± 1.5	6.5 ± 2.4	0.004	0.52 [0.06 ; 0.10]
Fatigue	7.4 ± 2.0	6.3 ± 2.4	0.02	0.49 [0.03 ; 0.96]
Pain	7.2 ± 1.3	4.3 ± 2.7	<0.0001	1.14 [0.64 ; 1.62]
Unstimulated salivary flow ≤ 0.01 mL/min	8 (40.0)	54 (56.3)	0.2	0.16 [-0.07 ; 0.40]
Schirmer's test ≤ 5 mm	13 (61.9)	60 (69.8)	0.6	0.08 [-0.15 ; 0.31]
ESSDAI	4.6 ± 4.9	4.0 ± 5.0	0.6	0.12 [-0.35 ; 0.59]
ESSDAI ≥ 5	7 (33.3)	28 (29.5)	0.8	0.04 [-0.18 ; 0.26]
Lymphoma	3 (13.6)	8 (8.1)	0.4	0.06 [-0.09 ; 0.21]
HAD anxiety on ASSESS inclusion	10.8 ± 4.7	9.5 ± 3.9	0.3	0.30 [-0.18 ; 0.78]
HAD depression on ASSESS inclusion	8.5 ± 3.9	5.2 ± 3.5	0.001	0.92 [0.43 ; 1.41]
Anti-SSA	10 (45.5)	69 (69.7)	0.03	0.24 [0.02 ; 0.47]
Anti-SSB	3 (13.6)	43 (43.4)	0.009	0.30 [0.12 ; 0.47]
Focus ≥ 1	20 (100)	78 (89.7)	0.2	0.10 [0.04 ; 0.17]
ESR (mm/h) (n=87), median [IQR]	17 [12 ; 21]	15 [9 ; 32]	0.8	0.17 [-0.34 ; 0.69]
C-reactive protein (mg/L) (n=108)	4.8 ± 10.8	4.8 ± 12.7	0.4	0.14 [-0.32 ; 0.61]
Gammaglobulin (g/L) (n=107), median [IQR]	10.9 [10.1 ; 16.4]	13.5 [10.9 ; 16.5]	0.07	0.32 [-0.16 ; 0.79]
Corticosteroids	2 (9.1)	18 (18.2)	0.5	0.09 [-0.05 ; 0.23]
Immunosuppressive drugs	2 (9.1)	15 (15.2)	0.7	0.06 [-0.08 ; 0.20]
Corticosteroids or immunosuppressive drugs	4 (18.2)	27 (27.7)	0.4	0.09 [-0.09 ; 0.27]
Hydroxychloroquine	9 (40.9)	30 (30.3)	0.5	0.10 [-0.12 ; 0.33]
Antidepressants	5 (22.7)	11 (11.1)	0.1	0.12 [-0.07 ; 0.30]
Anxiolytics	4 (18.2)	12 (12.2)	0.5	0.06 [-0.11 ; 0.23]
Antidepressants or anxiolytics	8 (36.4)	18 (18.2)	0.08	0.18 [-0.03 ; 0.40]

Data are given as mean ± SD or n (%) unless otherwise noted.

ACR: American College of Rheumatology; CI: confidence interval; SD: standard deviation; IQR: interquartile range; ESR: erythrocyte sedimentation rate; ESSPRI: EULAR Sjögren's Syndrome Patient Reported Index; ESSDAI: EULAR Sjögren's Syndrome Disease Activity Index; HAD: Hospital Anxiety and Depression scale; ASSESS: Assessment of Systemic Signs and Evolution in Sjögren's Syndrome cohort; NS: not significant.

Supplementary Table S3: Comparison of the characteristics of patients who did and did not have fibromyalgia according to the physician's opinion. Data are given as mean $\pm$ SD or n (%) unless otherwise noted.

	FM physician + N= 26	FM physician - N= 95	p-value	Effect size [95% CI]
Age (years)	63.9 $\pm$ 12.0	65.0 $\pm$ 12.1	0.7	0.10 [-0.33 ; 0.53]
Age upon diagnosis (years)	47.6 $\pm$ 12.1	48.6 $\pm$ 12.4	0.7	0.08 [-0.36 ; 0.52]
Time since diagnosis (years), median [IQR]	14.7 [13 ; 19]	15.1 [13.1 ; 19.5]	0.5	0.18 [-0.26 ; 0.62]
Females	25 (96.2)	91 (95.7)	1	0.004 [-0.08 ; 0.09]
ESSPRI	7.2 $\pm$ 1.3	5.6 $\pm$ 2.1	<0.0001	0.79 [0.34 ; 1.23]
Dryness	7.3 $\pm$ 1.5	6.6 $\pm$ 2.5	0.07	0.31 [-0.13 ; 0.75]
Fatigue	7.4 $\pm$ 1.9	6.3 $\pm$ 2.4	0.02	0.47 [0.03 ; 0.90]
Pain	6.8 $\pm$ 1.5	4.3 $\pm$ 2.7	<0.0001	1.01 [0.55 ; 1.46]
Unstimulated salivary flow $\leq$ 0.01 mL/min	11 (45.8)	51 (55.4)	0.5	0.10 [-0.13 ; 0.32]
Schirmer's test $\leq$ 5 mm	16 (64.0)	57 (69.5)	0.6	0.06 [-0.16 ; 0.27]
ESSDAI	4.4 $\pm$ 4.7	4.0 $\pm$ 5.1	0.7	0.07 [-0.37 ; 0.51]
ESSDAI $\geq$ 5	9 (36.0)	26 (28.6)	0.5	0.07 [-0.14 ; 0.28]
Lymphoma	2 (7.7)	9 (9.5)	1	0.02 [-0.10 ; 0.14]
HAD anxiety on ASSESS inclusion	10.7 $\pm$ 4.7	9.5 $\pm$ 3.9	0.3	0.29 [-0.16 ; 0.74]
HAD depression on ASSESS inclusion	7.8 $\pm$ 4.2	5.3 $\pm$ 3.5	0.01	0.69 [0.23 ; 1.14]
Anti-SSA	12 (46.2)	67 (70.5)	0.02	0.24 [0.03 ; 0.46]
Anti-SSB	4 (15.4)	42 (44.2)	0.007	0.29 [0.12 ; 0.46]
Focus $\geq$ 1	23 (95.8)	75 (90.4)	0.7	0.05 [-0.04 ; 0.16]
ESR (mm/h) (n=87), median [IQR]	13.5 [7 ; 18]	16 [10 ; 34]	0.1	0.45 [-0.03 ; 0.93]
C-reactive protein (mg/L) (n=108)	3.8 $\pm$ 10.1	45.1 $\pm$ 13.0	0.7	0.12 [-0.32 ; 0.55]
Gammaglobulin (g/L) (n=107), median [IQR]	10.2 [9.3 ; 14.4]	13.5 [11.1 ; 16.8]	0.02	0.41 [-0.04 ; 0.86]
Corticosteroids	1 (3.9)	19 (20)	0.07	0.16 [0.05 ; 0.27]
Immunosuppressive drugs	2 (7.7)	15 (15.8)	0.4	0.08 [-0.04 ; 0.21]
Corticosteroids or immunosuppressive drugs	3 (11.5)	28 (29.5)	0.08	0.18 [0.02 ; 0.33]
Hydroxychloroquine	10 (38.5)	29 (30.5)	0.5	0.08 [-0.13 ; 0.29]
Antidepressants	6 (23.1)	10 (10.5)	0.1	0.13 [-0.05 ; 0.30]
Anxiolytics	5 (19.2)	11 (11.7)	0.3	0.08 [-0.09 ; 0.24]
Antidepressants or anxiolytics	9 (34.6)	17 (17.9)	0.1	0.17 [-0.03 ; 0.37]

FM: fibromyalgia; CI: confidence interval; SD: standard deviation; IQR: interquartile range; ESR: erythrocyte sedimentation rate; ESSPRI: EULAR Sjögren's Syndrome Patient Reported Index; ESSDAI: EULAR Sjögren's Syndrome Disease Activity Index; HAD: Hospital Anxiety and Depression scale; ASSESS: Assessment of Systemic Signs and Evolution in Sjögren's Syndrome cohort; NS: not significant.

Supplementary Table S4: Comparison of the characteristics of patients who did and did not meet ACR 2016 criteria for fibromyalgia.

	ACR 2016 + N= 24	ACR 2016 - N=97	p-value	Effect size [95% CI]
Age (years)	64.0 ± 14.3	65.0 ± 11.4	0.7	0.08 [-0.36 ; 0.53]
Age upon diagnosis (years)	46.2 ± 13.2	48.9 ± 12.1	0.3	0.22 [-0.23 ; 0.67]
Time since diagnosis (years), median [IQR]	15.6 [13.2 ; 19.5]	15.1 [13 ; 18.8]	0.6	0.19 [-0.27 ; 0.64]
Females	22 (91.7)	94 (96.9)	0.2	0.05 [-0.06 ; 0.17]
ESSPRI	6.8 ± 1.4	5.8 ± 2.1	0.005	0.53 [0.07 ; 0.99]
Dryness	7.2 ± 1.7	6.6 ± 2.4	0.2	0.24 [-0.22 ; 0.69]
Fatigue	7.0 ± 2.0	6.4 ± 2.4	0.1	0.28 [-0.17 ; 0.74]
Pain6.	3 ± 2.2	4.5 ± 2.8	0.002	0.66 [0.20 ; 1.13]
ACR 2016 fatigue score				
- 0	0	9 (9.7)		
- 1	0	27 (29.0)	0.001	
- 2	13 (54.2)	38 (40.9)		
- 3	11 (45.8)	19 (20.4)		
Symptom severity score (SSS, 0-12)	8.5 ± 1.6	5.0 ± 2.8	<0.0001	
Widespread pain index (WPI, 0-19)	10 ± 2.5	4.0 ± 3.0	<0.0001	
Fibromyalgia severity score (FS, 0-31)	18.5 ± 3.6	9.1 ± 4.9	<0.0001	
Unstimulated salivary flow ≤ 0.01 mL/min	9 (39.1)	53 (57.0)	0.1	0.17 [-0.04 ; 0.40]
Schirmer's test ≤ 5 mm	13 (61.9)	60 (69.8)	0.6	0.08 [-0.15 ; 0.31]
ESSDAI	4.5 ± 4.8	4.0 ± 5.0	0.6	0.11 [-0.35 ; 0.57]
ESSDAI ≥ 5	8 (36.4)	27 (28.7)	0.6	0.08 [-0.14 ; 0.30]
Lymphoma	2 (8.3)	9 (9.3)	1	0.009 [-0.11 ; 0.13]
HAD anxiety on ASSESS inclusion	10 ± 3.8	9.7 ± 4.2	0.7	0.07 [-0.40 ; 0.54]
HAD depression on ASSESS inclusion	6.7 ± 4.5	5.7 ± 3.6	0.3	0.28 [0.19 ; 0.75]
Anti-SSA	11 (45.8)	68 (70.1)	0.02	0.24 [0.02 ; 0.46]
Anti-SSB	7 (29.2)	39 (40.2)	0.3	0.11 [-0.10 ; 0.32]
Focus ≥ 1	21 (91.3)	77 (91.7)	1	0.003 [-0.13 ; 0.13]
ESR (mm/h) (n=87), median [IQR]	17 [8; 19]	15.5 [9 ; 32]	0.3	0.32 [-0.17 ; 0.81]
C-reactive protein (mg/L) (n=108)	4.8 ± 10.6	4.7 ± 12.8	0.7	0.08 [-0.37 ; 0.53]
Gammaglobulin (g/L) (n=107), median [IQR]	10.9 [9.5 ; 15.3]	13.4 [11 ; 16.5]	0.2	0.19 [-0.27 ; 0.65]
Corticosteroids	1 (4.2)	19 (19.6)	0.1	0.15 [0.04 ; 0.27]
Immunosuppressive drugs	4 (16.7)	13 (13.4)	0.7	0.03 [-0.13 ; 0.20]
Corticosteroids or immunosuppressive drugs	4 (16.7)	27 (27.8)	0.3	0.11 [-0.06 ; 0.29]
Hydroxychloroquine	11 (45.8)	28 (28.9)	0.1	0.17 [-0.05 ; 0.39]
Antidepressants	6 (25)	10 (10.3)	0.08	0.15 [-0.04 ; 0.33]
Anxiolytics	3 (12.5)	13 (13.5)	1	0.01 [-0.14 ; 0.16]
Antidepressants or anxiolytics	8 (33.3)	18 (18.6)	0.1	0.15 [-0.06 ; 0.35]

Data are given as mean ± SD or n (%) unless otherwise noted.

ACR: American College of Rheumatology; CI: confidence interval; SD: standard deviation; IQR: interquartile range; ESR: erythrocyte sedimentation rate; ESSPRI: EULAR Sjögren's Syndrome Patient Reported Index; ESSDAI: EULAR Sjögren's Syndrome Disease Activity Index; HAD: Hospital Anxiety and Depression scale; ASSESS: Assessment of Systemic Signs and Evolution in Sjögren's Syndrome cohort; NS: not significant.